Jan 9 (Reuters) - 3D Medicines Inc 1244.HK:
NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NMPA
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Jan 9 (Reuters) - 3D Medicines Inc 1244.HK:
NEW DRUG APPLICATION FOR FIRST-LINE TREATMENT OF BILIARY TRACT CANCER OF ENVAFOLIMAB ACCEPTED BY NMPA
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Comments